Regressin immunostimulant derived from Mycobacterium phelei data

A preliminary statistical analysis of a Phase II/III trial of Regressin in 68 patients treated for up to 78 weeks shows that the response rate of previously untreated patients was 52 percent. The response in patients who had failed to respond to conventional BCG (bacille Calmette-Guerin) therapy was 22 percent.

Side-effects were lower with Regressin than those reported in the medical literature for BCG. ...